SG11201603115YA - Conjugates of somatostatin and its analogs - Google Patents
Conjugates of somatostatin and its analogsInfo
- Publication number
- SG11201603115YA SG11201603115YA SG11201603115YA SG11201603115YA SG11201603115YA SG 11201603115Y A SG11201603115Y A SG 11201603115YA SG 11201603115Y A SG11201603115Y A SG 11201603115YA SG 11201603115Y A SG11201603115Y A SG 11201603115YA SG 11201603115Y A SG11201603115Y A SG 11201603115YA
- Authority
- SG
- Singapore
- Prior art keywords
- somatostatin
- conjugates
- analogs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361894226P | 2013-10-22 | 2013-10-22 | |
| PCT/US2014/061844 WO2015061503A1 (en) | 2013-10-22 | 2014-10-22 | Conjugates of somatostatin and its analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201603115YA true SG11201603115YA (en) | 2016-05-30 |
Family
ID=52993525
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201603115YA SG11201603115YA (en) | 2013-10-22 | 2014-10-22 | Conjugates of somatostatin and its analogs |
| SG10201803370XA SG10201803370XA (en) | 2013-10-22 | 2014-10-22 | Conjugates of somatostatin and its analogs |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201803370XA SG10201803370XA (en) | 2013-10-22 | 2014-10-22 | Conjugates of somatostatin and its analogs |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10086049B2 (en) |
| EP (1) | EP3060230A4 (en) |
| JP (1) | JP2016534064A (en) |
| KR (1) | KR20160075665A (en) |
| CN (1) | CN106232131A (en) |
| AU (1) | AU2014340095A1 (en) |
| CA (1) | CA2928407A1 (en) |
| MX (1) | MX2016005285A (en) |
| SG (2) | SG11201603115YA (en) |
| WO (1) | WO2015061503A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3555280A4 (en) * | 2016-12-19 | 2020-09-09 | The Regents of The University of California | Dual-enzyme responsive peptides |
| JOP20190245A1 (en) | 2017-04-20 | 2019-10-15 | Novartis Ag | Sustained release delivery systems comprising traceless linkers |
| EP3630189A4 (en) * | 2017-05-24 | 2021-06-23 | The Board of Regents of The University of Texas System | Linkers for antibody drug conjugates |
| CA3075670C (en) * | 2017-09-19 | 2022-05-31 | Immunwork Inc. | Pharmaceutical constructs with enhanced binding affinity with albumin |
| TW202027794A (en) | 2018-10-03 | 2020-08-01 | 瑞士商諾華公司 | Sustained delivery of angiopoetin-like 3 polypeptides |
| WO2021067458A1 (en) * | 2019-09-30 | 2021-04-08 | Beijing Xuanyi Pharmasciences Co., Ltd. | Protein-macromolecule conjugates and methods of use thereof |
| US20230098031A1 (en) * | 2019-12-11 | 2023-03-30 | The General Hospital Corporation | Methods for cell imaging |
| CN114409736B (en) * | 2022-01-28 | 2023-09-15 | 中国科学院精密测量科学与技术创新研究院 | Phasing arrangement medium based on amphiphilic oligopeptide and preparation method and application thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214792B1 (en) * | 1996-04-12 | 2001-04-10 | David Lew Simon | Method for treating acute and severe diarrhea |
| US6706289B2 (en) | 2000-10-31 | 2004-03-16 | Pr Pharmaceuticals, Inc. | Methods and compositions for enhanced delivery of bioactive molecules |
| US7452868B2 (en) | 2005-03-11 | 2008-11-18 | Indevus Pharmaceuticals, Inc. | Controlled release formulations of octreotide |
| GB0711656D0 (en) | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
| JP5536053B2 (en) | 2008-06-25 | 2014-07-02 | エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド． | Octreotide implant with release agent |
| CN102076331B (en) | 2008-06-26 | 2013-12-18 | 普罗林科斯有限责任公司 | Prodrugs and drug-macromolecule conjugates having controlled drug release rates |
| US8640315B1 (en) | 2009-10-28 | 2014-02-04 | Robert E. Nikkel | Rotating adapter assembly |
| CN102711728B (en) * | 2010-01-13 | 2016-01-20 | 益普生制药股份有限公司 | For delaying the preparation method of the pharmaceutical composition discharging somatostatin analogue |
| WO2011140376A1 (en) | 2010-05-05 | 2011-11-10 | Prolynx Llc | Controlled drug release from dendrimers |
| JP5977229B2 (en) | 2010-05-05 | 2016-08-24 | プロリンクス リミテッド ライアビリティ カンパニー | Sustained release from macromolecular conjugates |
| JP5964815B2 (en) * | 2010-05-05 | 2016-08-03 | プロリンクス リミテッド ライアビリティ カンパニー | Controlled release drug from solid carrier |
| SG11201400444VA (en) * | 2011-09-07 | 2014-04-28 | Prolynx Llc | Hydrogels with biodegradable crosslinking |
| BR112014013693B1 (en) | 2011-12-05 | 2023-01-31 | Camurus Ab | PREFORMULATION, AND, USE OF A PREFORMULATION |
-
2014
- 2014-10-22 AU AU2014340095A patent/AU2014340095A1/en not_active Abandoned
- 2014-10-22 SG SG11201603115YA patent/SG11201603115YA/en unknown
- 2014-10-22 CA CA2928407A patent/CA2928407A1/en not_active Abandoned
- 2014-10-22 CN CN201480065992.4A patent/CN106232131A/en active Pending
- 2014-10-22 JP JP2016525548A patent/JP2016534064A/en active Pending
- 2014-10-22 EP EP14856508.8A patent/EP3060230A4/en not_active Withdrawn
- 2014-10-22 WO PCT/US2014/061844 patent/WO2015061503A1/en active Application Filing
- 2014-10-22 SG SG10201803370XA patent/SG10201803370XA/en unknown
- 2014-10-22 US US15/030,353 patent/US10086049B2/en active Active
- 2014-10-22 KR KR1020167013614A patent/KR20160075665A/en not_active Application Discontinuation
- 2014-10-22 MX MX2016005285A patent/MX2016005285A/en unknown
-
2018
- 2018-06-22 US US16/016,409 patent/US10413594B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20180296648A1 (en) | 2018-10-18 |
| CA2928407A1 (en) | 2015-04-30 |
| CN106232131A (en) | 2016-12-14 |
| US10086049B2 (en) | 2018-10-02 |
| KR20160075665A (en) | 2016-06-29 |
| US20160271227A1 (en) | 2016-09-22 |
| JP2016534064A (en) | 2016-11-04 |
| US10413594B2 (en) | 2019-09-17 |
| AU2014340095A1 (en) | 2016-05-26 |
| EP3060230A4 (en) | 2017-06-14 |
| WO2015061503A1 (en) | 2015-04-30 |
| EP3060230A1 (en) | 2016-08-31 |
| SG10201803370XA (en) | 2018-06-28 |
| MX2016005285A (en) | 2016-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190101T1 (en) | Therapeutic uses of empagliflozin | |
| IL276289B (en) | Therapeutic uses of empagliflozin | |
| IL279395A (en) | Vaccine composition | |
| HK1213818A1 (en) | Therapeutic uses of empagliflozin | |
| SG11201506876XA (en) | Modification of polypeptides | |
| HK1221416A1 (en) | Formulations of oxabicycloheptanes and oxabicycloheptenes | |
| HRP20181710T1 (en) | Use of benzimidazole-proline derivatives | |
| SG11201603115YA (en) | Conjugates of somatostatin and its analogs | |
| HK1224324A1 (en) | Treatment of coal | |
| EP2971029C0 (en) | Preparation of malto-oligosaccharides | |
| GB2516136B (en) | Colenterazine analogs | |
| EP2957317A4 (en) | High functionality bioelectrode | |
| HK1204916A1 (en) | Pharmaceutical application of anhydroicaritin | |
| PL3049378T3 (en) | Preparation of radioiodinated 3-fluoropropyl-nor-beta-cit | |
| HK1222560A1 (en) | Anti-influenza compositions and methods | |
| GB201300324D0 (en) | Improvements to letter-plates | |
| KR102216470B9 (en) | Composition of Natural Substance | |
| PL3071575T3 (en) | Preparation of normorphinans | |
| HK1198422A1 (en) | Novel uses of colossolactones | |
| TWM475821U (en) | Structure of mosquito-catch | |
| TWM475524U (en) | Structure of rivet-pulling | |
| TWM475672U (en) | Improved structure of signage | |
| GB201304608D0 (en) | BenTime of Yisrael operable arrangement |